Form 13-F position report

KALVISTA PHARMACEUTICALS IN

Reported by WELLINGTON MANAGEMENT GROUP LLP

KALV CUSIP 483497103 Manager CIK 0000902219

Reported 0 shares, down 776,510 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2022
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 14 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 23966000
2022-03-31 19851000
2022-06-30 4626000
2022-09-30 11267000
2022-12-31 0
2024-03-31 941269
2024-06-30 989791
2024-09-30 1365548
2024-12-31 1040650
2025-03-31 1457133
2025-06-30 1502434
2025-09-30 1535314
2025-12-31 1976422
2026-03-31 2159184
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for KALVISTA PHARMACEUTICALS IN held by WELLINGTON MANAGEMENT GROUP LLP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -107,262 (-100.0%) 0 $0 2026-08-14
Q1 2026 Reduced 107,262 -15,117 (-12.4%) < 0.01% $2,159,184 2026-05-15
Q4 2025 Reduced 122,379 -3,673 (-2.9%) < 0.01% $1,976,422 2026-02-17
Q3 2025 Reduced 126,052 -6,848 (-5.2%) < 0.01% $1,535,314 2025-11-14
Q2 2025 Added 132,900 +6,632 (5.3%) < 0.01% $1,502,434 2025-08-14
Q1 2025 Added 126,268 +3,405 (2.8%) < 0.01% $1,457,133 2025-05-13
Q4 2024 Added 122,863 +4,940 (4.2%) < 0.01% $1,040,650 2025-02-12
Q3 2024 Added 117,923 +33,900 (40.3%) < 0.01% $1,365,548 2024-11-14
Q2 2024 Added 84,023 +4,658 (5.9%) < 0.01% $989,791 2024-08-14
Q1 2024 New 79,365 +79,365 (0.0%) < 0.01% $941,269 2024-05-15
Q4 2022 Reduced 0 -776,510 (-100.0%) 0 $0 2023-02-13
Q3 2022 Added 776,510 +306,377 (65.2%) < 0.01% $11,267,000 2022-11-14
Q2 2022 Reduced 470,133 -876,609 (-65.1%) < 0.01% $4,626,000 2022-08-15
Q1 2022 Reduced 1,346,742 -464,763 (-25.7%) < 0.01% $19,851,000 2022-05-16
Q4 2021 Reduced 1,811,505 -19,936 (-1.1%) < 0.01% $23,966,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

114 managers reported KALVISTA PHARMACEUTICALS IN for Q4 2022.

Managers reporting KALVISTA PHARMACEUTICALS IN in Q4 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
TCG Crossover Management LLC New 3,395,495 +3,395,495 4.05% $22,953,546 1 qtr
Frazier Life Sciences Management L P Added 3,238,859 +1,666,667 1.36% $21,894,687 4 qtrs
TANG CAPITAL MANAGEMENT LLC Added 3,196,446 +1,396,446 3.14% $21,607,975 4 qtrs
VR Adviser LLC New 2,916,667 +2,916,667 3.32% $19,716,669 1 qtr
BlackRock Inc Reduced 1,572,421 -133,727 < 0.01% $10,629,566 24 qtrs
FMR LLC Added 1,311,002 +152,617 < 0.01% $8,862,374 16 qtrs
JEFFERIES FINANCIAL GROUP INC New 1,200,000 +1,200,000 0.06% $8,112,000 1 qtr
VANGUARD GROUP INC Added 1,152,673 +2,812 < 0.01% $7,792,070 25 qtrs
SUVRETTA CAPITAL MANAGEMENT LLC Reduced 1,072,302 -634,798 0.3% $7,248,762 12 qtrs
ADAGE CAPITAL PARTNERS GP L L C Reduced 1,064,339 -15,000 0.02% $7,194,932 18 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 13, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.